Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443116 · ClinicalTrials.gov registry record · Phase 2
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT02443116: Completed Phase 2 study, sponsored by NGM Biopharmaceuticals.
NCT02443116 is a Phase 2 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 254 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02443116, a Phase 2 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
Primary Outcome
Absolute liver fat content was assessed using magnetic resonance imaging (MRI).
Interventions
- OTHER Placebo
- BIOLOGICAL NGM282
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2015-07-31 |
| Est. Completion | 2020-01-17 |
| Phase | Phase 2 |
What the finished NCT02443116 record still lists
NCT02443116 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02443116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02443116 about?
NCT02443116 is a clinical study titled "Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)". The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
What is the current status of trial NCT02443116?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2015-07-31. Estimated completion is 2020-01-17.
What interventions are being tested in trial NCT02443116?
The interventions under investigation include: Placebo (OTHER), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02443116?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02443116's enrollment target sits among peer trials
254 219th of 2000 higher than 1,781 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI